Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia

Veronica Wendy Setiawan, Fredrick Schumacher, Jennifer Prescott, Jeffrey Haessler, Jennifer Malinowski, Nicolas Wentzensen, Hannah Yang, Stephen Chanock, Louise Brinton, Patricia Hartge, Jolanta Lissowska, S. Lani Park, Iona Cheng, William S. Bush, Dana C. Crawford, Giske Ursin, Pamela Horn-Ross, Leslie Bernstein, Lingeng Lu, Harvey RischHerbert Yu, Lori C. Sakoda, Jennifer Doherty, Chu Chen, Rebecca Jackson, Shagufta Yasmeen, Michele Cote, Jonathan M. Kocarnik, Ulrike Peters, Peter Kraft, Immaculata De Vivo, Christopher A. Haiman, Charles Kooperberg, Loic Le Marchand

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Genome-wide association studies (GWAS) have identified a large number of cancer-associated single nucleotide polymorphisms (SNPs), several of which have been associated with multiple cancer sites suggesting pleiotropic effects and shared biological mechanisms across some cancers. We hypothesized that SNPs associated with other cancers may be additionally associated with endometrial cancer. We examined 213 SNPs previously associated with 14 other cancers for their associations with endometrial cancer in 3758 endometrial cancer cases and 5966 controls of European ancestry from two consortia: Population Architecture Using Genomics and Epidemiology and the Epidemiology of Endometrial Cancer Consortium. Study-specific logistic regression estimates adjusted for age, body mass index and the most significant principal components of genetic ancestry were combined using fixedeffect meta-analysis to evaluate the association between each SNP and endometrial cancer risk. A Bonferroni-corrected P value of 2.35 × 10-4 was used to determine statistical significance of the associations. SNP rs7679673, ~6.3 kb upstream of TET2 and previously reported to be associated with prostate cancer risk, was associated with endometrial cancer risk in the direction opposite to that for prostate cancer [meta-analysis odds ratio = 0.87 (per copy of the C allele), 95% confidence interval = 0.81, 0.93; P = 7.37 × 10-5] with no evidence of heterogeneity across studies (P heterogeneity = 0.66). This pleiotropic analysis is the first to suggest TET2 as a susceptibility locus for endometrial cancer.

Original languageEnglish (US)
Article numberbgu107
Pages (from-to)2068-2073
Number of pages6
Issue number9
StatePublished - 2014

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia'. Together they form a unique fingerprint.

Cite this